Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LFST LifeStance Health Group	$5.08 +2.4%	$5.89	$4.64 ▼ $8.61	$1.93B	1.23	1.64 million shs	3.23 million shs
OSH Oak Street Health	$39.00	$37.57	$13.29 ▼ $39.00	$9.52B	2.23	5.76 million shs	N/A
PRVA Privia Health Group	$22.01 +1.9%	$23.27	$16.37 ▼ $26.09	$2.63B	0.83	745,295 shs	1.13 million shs
TEVA Teva Pharmaceutical Industries	$17.12 +0.9%	$16.53	$12.47 ▼ $22.80	$19.46B	0.6	10.22 million shs	9.51 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LFST LifeStance Health Group	+2.42%	+0.79%	-7.47%	-23.03%	-4.33%
OSH Oak Street Health	0.00%	0.00%	0.00%	0.00%	0.00%
PRVA Privia Health Group	+1.85%	-1.70%	-3.72%	-3.80%	+30.55%
TEVA Teva Pharmaceutical Industries	+0.94%	+1.32%	+1.03%	+9.21%	+3.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LFST LifeStance Health Group	2.6376 of 5 stars	3.4	2.0	0.0	0.0	2.5	2.5	0.6
OSH Oak Street Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRVA Privia Health Group	4.3459 of 5 stars	4.5	3.0	0.0	0.0	2.8	3.3	1.9
TEVA Teva Pharmaceutical Industries	4.4314 of 5 stars	4.6	5.0	0.0	0.0	2.7	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LFST LifeStance Health Group	2.83	Moderate Buy	$8.50	67.32% Upside
OSH Oak Street Health	0.00	N/A	N/A	N/A
PRVA Privia Health Group	3.00	Buy	$27.77	26.17% Upside
TEVA Teva Pharmaceutical Industries	3.20	Buy	$24.44	42.79% Upside

Current Analyst Ratings Breakdown

Latest OSH, LFST, PRVA, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
5/28/2025	PRVA Privia Health Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $32.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	LFST LifeStance Health Group	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.50
5/27/2025	PRVA Privia Health Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$23.00 ➝ $24.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
4/28/2025	PRVA Privia Health Group	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$29.00 ➝ $29.00
4/28/2025	TEVA Teva Pharmaceutical Industries	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/15/2025	PRVA Privia Health Group	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$24.00 ➝ $26.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LFST LifeStance Health Group	$1.28B	1.54	$0.04 per share	125.08	$3.78 per share	1.34
OSH Oak Street Health	$2.16B	4.40	N/A	N/A	($1.10) per share	-35.45
PRVA Privia Health Group	$1.80B	1.49	$0.18 per share	119.76	$5.70 per share	3.86
TEVA Teva Pharmaceutical Industries	$16.54B	1.19	$3.40 per share	5.04	$4.74 per share	3.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LFST LifeStance Health Group	-$57.44M	-$0.10	N/A	N/A	N/A	-2.78%	-2.47%	-1.69%	8/14/2025 (Estimated)
OSH Oak Street Health	-$509.20M	-$2.21	N/A	N/A	N/A	-23.57%	N/A	-25.08%	N/A
PRVA Privia Health Group	$14.39M	$0.12	183.43	81.52	3.46	0.87%	2.32%	1.38%	8/14/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.51	0.87	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)

Latest OSH, LFST, PRVA, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LFST LifeStance Health Group	N/A	N/A	N/A	N/A	N/A
OSH Oak Street Health	N/A	N/A	N/A	N/A	N/A
PRVA Privia Health Group	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LFST LifeStance Health Group	0.19	1.47	1.47
OSH Oak Street Health	N/A	1.41	1.41
PRVA Privia Health Group	N/A	1.88	1.88
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LFST LifeStance Health Group	85.50%
OSH Oak Street Health	92.04%
PRVA Privia Health Group	94.48%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
LFST LifeStance Health Group	6.60%
OSH Oak Street Health	11.55%
PRVA Privia Health Group	10.70%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LFST LifeStance Health Group	10,218	388.88 million	363.21 million	Optionable
OSH Oak Street Health	6,000	244.00 million	215.82 million	Not Optionable
PRVA Privia Health Group	1,140	121.92 million	108.88 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

OSH, LFST, PRVA, and TEVA Headlines

Recent News About These Companies

Teva Pharmaceutical Industries Ltd. - Page 2 - The New York Times

June 25 at 5:21 AM | nytimes.com

Retirement Systems of Alabama Takes Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 25 at 3:43 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd: Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY (fremanezumab) for the Prevention of Chronic ...

June 25 at 12:18 AM | finanznachrichten.de

Teva Pharmaceutical Industries Presents Final Analysis of PEARL Study Demonstrating Sustained Effectiveness of AJOVY in Migraine Prevention at EAN 2025 Congress - Nasdaq

June 25 at 12:18 AM | nasdaq.com

TEVA Teva Pharmaceutical Industries Limited - Seeking Alpha

June 25 at 12:18 AM | seekingalpha.com

Teva reports final analysis of migraine prevention trial of Ajovy

June 24 at 7:17 PM | msn.com

Whalen Wealth Management Inc. Takes Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 23 at 6:00 AM | marketbeat.com

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

June 23 at 3:00 AM | globenewswire.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Reduced by QRG Capital Management Inc.

June 20, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd: Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

June 18, 2025 | finanznachrichten.de

Teva and Fosun Pharma partner on early-stage oncology drug

June 18, 2025 | pharmatimes.com

Janney Montgomery Scott LLC Raises Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 18, 2025 | marketbeat.com

Teva 2024 Healthy Future Report: Advancing Innovation and Collaboration

June 17, 2025 | csrwire.com

Teva Pharmaceutical Stock Surges Despite Recent Dip NYSE Composite

June 17, 2025 | kalkinemedia.com

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

June 17, 2025 | zacks.com

Teva to collaborate with Fosun Pharma for TEV-56278

June 17, 2025 | finance.yahoo.com

Teva and Fosun ink deal on TEV-56278 development

June 17, 2025 | thepharmaletter.com

GAMMA Investing LLC Boosts Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 17, 2025 | marketbeat.com

Eliyahu Kalif Sells 55,775 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

June 16, 2025 | gurufocus.com

Handelsbanken Fonder AB Buys Shares of 15,792 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 16, 2025 | marketbeat.com

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

June 16, 2025 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSH, LFST, PRVA, and TEVA Company Descriptions

LifeStance Health Group NASDAQ:LFST

$5.08 +0.12 (+2.42%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$5.08 0.00 (0.00%)

As of 08:00 AM Eastern

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

Oak Street Health NYSE:OSH

Oak Street Health, Inc., together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2021, it operated 129 centers in 19 states, including Illinois, Michigan, Pennsylvania, Ohio, and Texas. The company was founded in 2012 and is headquartered in Chicago, Illinois.

Privia Health Group NASDAQ:PRVA

$22.01 +0.40 (+1.85%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$22.18 +0.17 (+0.78%)

As of 08:04 AM Eastern

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia.

Teva Pharmaceutical Industries NYSE:TEVA

$17.12 +0.15 (+0.88%)

Closing price 06/24/2025 03:59 PM Eastern

Extended Trading

$17.24 +0.12 (+0.68%)

As of 08:13 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time